Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2299c8d4d6c6483

Jump to content

IHCH-8134

From Wikipedia, the free encyclopedia
(Redirected from C23H28N2O2)

IHCH-8134
Clinical data
Drug classSerotonin 5-HT2A receptor agonist
Identifiers
  • (6bR,10aS)-8-(3-(2-methoxyphenyl)propyl)-1,2,6b,7,8,9,10,10a-octahydro-[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole
PubChem CID
Chemical and physical data
FormulaC23H28N2O2
Molar mass364.489 g·mol−1
3D model (JSmol)
  • [H][C@@]12[C@@](CCN(CCCC3=CC=CC=C3OC)C2)([H])N4CCOC5=C4C1=CC=C5
  • InChI=1S/C23H28N2O2/c1-26-21-9-3-2-6-17(21)7-5-12-24-13-11-20-19(16-24)18-8-4-10-22-23(18)25(20)14-15-27-22/h2-4,6,8-10,19-20H,5,7,11-16H2,1H3/t19-,20-/m0/s1
  • Key:XIZOEKLHAJIDMD-PMACEKPBSA-N

IHCH-8134 is a serotonin 5-HT2A receptor agonist of the oxazinopyridoindole family. It was derived by structural simplification of the serotonin 5-HT2A receptor antagonist and atypical antipsychotic lumateperone. Another related compound is the pyridopyrroloquinoxaline IHCH-7079, which was found to be a non-hallucinogenic biased serotonin 5-HT2A receptor agonist that was active in antidepressant assays but did not produce psychedelic-like responding in mice.[1][2][3]

See also

[edit]

References

[edit]
  1. US 6552017, Robichaud AJ, Lee T, Deng W, Mitchell IS, Yang MG, Haydar S, Chen W, Mc Clung CD, Calvello EJ, Zawrotny DM, "Substituted heterocycle fused gamma-carbolines.", issued 22 April 2003, assigned to Bristol Myers Squibb Pharma Co.
  2. US 9315504, Tomesch JC, Li P, Yao W, Zhang Q, Beard JD, Thompson AS, Cheng H, Wennogle LP, "Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof", issued 19 April 2016, assigned to Intra Cellular Therapies Inc.
  3. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579). New York, N.Y.: 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.
[edit]